Pricing Log in Create free account
Saturday 17 October 2026 Export UTMD’s income statement to Excel — free account

Utah Medical Products, Inc.

UTMD Healthcare Medical Instruments & Supplies

Utah Medical Products, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, down 5.83% from fiscal 2024. In the quarter to June 2026, revenue fell 14.3%, EPS fell 10.6% and free cash flow fell 55.7%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

74.51 0.41 −0.55%
Market cap
$237.8M
P/E
22.7×
Fwd P/E
28.7×
Dividend yield
1.66%
F-score
6/9
Altman Z
36.25
Beneish M
−2.68
Dividend safety
82/100
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 7.35%

Capital & Financial Ratios $m

Market Cap 237.78
Revenue 36.11
Net Income 10.49
Free Cash Flow 11.45
Net Debt (87.53)
Current Ratio 48.62 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 22.72
Fwd P/E 28.70
P/S ratio 6.57
P/B ratio 1.94
Past 5Y EPS Growth 3.43%
This Y EPS Growth —
Next Y EPS Growth —
Next Y revenue growth (10.03%) (below 0%: weak)
Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.2×, against a ten-year median of 5.3×; over the ten years it ranged from 2.3× in 2025 to 8.8× in 2018.
P/E against its own 10 years 70.29%
10-year low 10-year high
P/S against its own 10 years 53.63%
10-year low 10-year high
P/B against its own 10 years 21.93%
10-year low 10-year high
EV/Sales against its own 10 years 26.39%
10-year low 10-year high
EV/FCF against its own 10 years 52.40%
10-year low 10-year high

Dividends

Payout Ratio 0.38
Annual Dividend Rate 1.24
Annual Dividend Yield 1.66%
total individual payouts
2026 0.93
0.31
0.31
0.31
2025 1.23
0.31
0.31
0.31
0.31
2024 1.21
0.30
0.30
0.30
0.31
2023 1.19
0.30
0.30
0.30
0.30
2022 1.17
0.29
0.29
0.29
0.30
2021 0.86
0.29
0.29
0.29
2.00
2020 1.13
0.28
0.28
0.28
0.29
2019 1.11
0.28
0.28
0.28
0.28
2018 1.09
0.27
0.27
0.27
0.28
2017 1.07
0.27
0.27
0.27
0.27
2016 1.05
0.26
0.26
0.26
0.27
special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 93 83 86 88
Receivables 3 4 4 4
Inventory 10 9 8 9
Other — — — —
106 96 98 101
2023 2024 2025 Q'26
Payables 1 1 1 1
ST’ Debt — — — —
Other — — — —
5 4 3 2

Compound Annual Growth %

10y 5y 3y
Sales (0.42%) (1.80%) (9.68%)
Cash Flow 0.63% (6.11%) (11.43%)
Earnings (0.48%) 0.89% (11.84%)
Book Value 5.53% 3.01% 1.44%

Revenue $m

Mar Jun Sep Dec Year
’26 9 9 — — —
’25 10 10 10 9 39
’24 11 10 10 9 41
’23 13 13 13 12 50
’22 12 13 13 14 52
’21 11 13 13 13 49
’20 11 9 10 12 42
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 3 1 — — —
’25 4 3 4 3 15
’24 5 3 4 3 15
’23 7 5 5 5 22
’22 5 5 6 6 21
’21 6 5 6 5 21
’20 6 4 5 6 20
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 3 1 — — —
’25 4 3 4 3 14
’24 5 3 4 3 15
’23 7 5 5 5 22
’22 5 5 5 6 20
’21 6 4 6 5 21
’20 5 3 5 6 19
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 0.82 0.84 — — —
’25 0.92 0.94 0.82 0.80 3.48
’24 1.09 0.98 1.02 0.86 3.96
’23 1.16 1.15 1.08 1.18 4.57
’22 0.96 1.12 1.18 1.25 4.52
’21 0.83 0.94 1.15 1.13 4.04
’20 0.84 0.36 0.80 0.93 2.94
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 54.20 58.50 73.98 76.60 75.33 81.01 80.10 75.00 60.39 51.26

Analyst estimates 2026–2028

Powerpack
High 75.00 85.00 117.65 112.26 109.99 133.87 109.50 101.41 85.76 65.56
People
People Employees 184 183 173 193 192 211 221 190 167 152
Revenue/emp, $m 0.21 0.23 0.24 0.24 0.22 0.23 0.24 0.26 0.24 0.25
Income, $m
Income, $m Revenue 39 41 42 47 42 49 52 50 41 39
Gross margin, % 60.28 63.73 62.64 62.82 60.57 63.03 61.58 59.81 59.03 57.12
EBT 16 19 19 18 14 19 21 20 17 14
EBT margin, % 41.79 46.08 46.33 38.13 32.81 38.86 39.52 40.00 41.08 36.63
Net income 12 9 19 15 11 15 16 17 14 11
Depreciation 3 3 3 7 7 7 7 6 3 3
Per share, $
Per share, $ Revenue 10.48 11.14 11.26 12.61 11.53 13.45 14.37 13.84 11.68 11.89
Earnings 3.22 2.28 4.95 3.94 2.94 4.04 4.52 4.57 3.96 3.48
Cash flow 3.87 4.55 4.51 4.58 5.50 5.81 5.81 6.14 4.23 4.53
Capex (0.88) (0.43) 0.12 (5.79) (0.24) (0.15) (0.22) (0.18) (0.06) (0.11)
Free cash flow 2.99 4.12 4.64 (1.21) 5.27 5.66 5.59 5.96 4.17 4.42
Book value 18.46 21.01 23.86 27.17 28.11 29.38 31.41 35.36 33.52 36.81
Shares, m 4 4 4 4 4 4 4 4 4 3
Valuation, ×
Valuation, × P/E 22.24 34.63 16.78 27.39 28.77 24.69 21.68 18.27 15.56 16.08
P/S 6.82 7.12 7.38 8.56 7.31 7.43 6.80 6.03 5.26 4.71
P/B 3.87 3.77 3.48 3.97 3.00 3.40 3.11 2.36 1.83 1.52
EV/Sales 6.17 6.18 6.18 7.67 6.11 6.21 5.38 4.20 3.26 2.51
EV/FCF 21.60 16.72 15.02 (80.21) (149.60) (873.06) 13.85 9.75 9.12 6.74
Cash, $m
Cash, $m Operating cash flow 15 17 17 17 20 21 21 22 15 15
Capex (3) (2) 0 (22) (1) (1) (1) (1) 0 0
Free cash flow 11 15 17 (4) 19 21 20 22 15 14
Balance, $m
Balance, $m Working capital 31 44 56 51 58 69 84 102 93 95
Total debt — — — 0 0 0 0 — — —
Net debt (26) (40) (51) (43) (52) (61) (75) (93) (83) (86)
Shareholders’ equity 69 78 89 101 103 107 114 128 117 119
Returns, %
Returns, % ROA 15.61 10.07 19.28 14.06 9.75 13.01 13.76 12.83 10.76 9.21
ROIC 23.59 31.13 30.85 18.90 16.72 25.56 31.55 29.58 24.66 21.26
ROE 17.46 11.54 22.21 15.50 10.59 14.09 14.88 13.72 11.29 9.54
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Utah Medical Products, Inc. vs peers in Medical Instruments & Supplies (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
NNNN Anbio Biotechnology $474.8M — — — — — — — Compare
EMBC Embecta Corp. $365.5M 4.2× 3.8× −8.05% (below 0%: shrinking) −53.85% (below 0%: shrinking) −49.63% (below 0%: shrinking) 56.42% 17.92% Compare
ZJYL Jin Medical International Ltd. $340.9M — — — — −8,074.17% (below 0%: shrinking) 34.44% 0.00% Compare
SMTI Sanara MedTech Inc. $322.4M — (loss-making) 125× +9.04% (above 0%: growing) n/m +131.28% (above 0%: growing) 92.96% 6.33% Compare
OSUR OraSure Technologies, Inc. $262.8M — (loss-making) — (loss-making) −1.93% (below 0%: shrinking) n/m −1.40% (below 0%: shrinking) 43.46% 17.76% Compare
UTMD Utah Medical Products, Inc. $237.8M 22.7× 28.7× −14.31% (below 0%: shrinking) −10.64% (below 0%: shrinking) −55.74% (below 0%: shrinking) 55.79% 31.06%
PDEX Pro-Dex, Inc. $194.1M 13.8× 23.5× +16.65% (above 0%: growing) +143.24% (above 0%: growing) −78.95% (below 0%: shrinking) 34.75% 17.29% Compare
KRMD KORU Medical Systems, Inc. $139.9M — (loss-making) — (loss-making) +18.15% (above 0%: growing) n/m +26.17% (above 0%: growing) 65.14% 5.21% Compare
NYXH Nyxoah SA $121.2M — (loss-making) — (loss-making) +486.62% (above 0%: growing) n/m +4.01% (above 0%: growing) 59.73% (268.25%) Compare
Median of peers $292.6M — 23.5× +12.85% — −1.40% 56.42% 6.33%

All 55 Medical Instruments & Supplies stocks →

Utah Medical Products, Inc. (UTMD) key facts

  • Concern: Utah Medical Products, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $38.5 million, down 5.83% from fiscal 2024.
  • Concern: Net income was $11.3 million, or $3.48 per share (basic), a net margin of 29.3%.
  • Utah Medical Products, Inc. (UTMD) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, UTMD traded at $74.51, a market capitalization of $237.8 million.
  • At that price the stock trades at 22.7× trailing-twelve-month earnings and 6.6× sales; its P/E is higher than 70% of its own readings over the past ten years.
  • Utah Medical Products, Inc. pays an annual dividend of $1.24 per share, a yield of 1.66%, with a payout ratio of 37.8%.
  • Return on equity was 9.54% and debt-to-equity 0.00.
  • Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 36.25 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Utah Medical Products, Inc. (UTMD) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/UTMD · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com